Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
5
Neutral
6
Bullish
3
Bearish
37
Neutral
6
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Healthcare Services
Healthcare Service Provider
26 Cr
Low Risk
23.3
59.7
1.6
2.0
150.50
74.00
Sales CAGR
Profit CAGR
ROE
ROCE
Sharma East India Hosp and Medical Research Ltd (SHARMEH) is currently trading at 80.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sharma East India Hospitals & Medical Research Limited operates Jaipur Hospital, a multi-specialty hospital in Jaipur, Rajasthan, offering inpatient, surgical, cardiac and replacement surgery services while also engaging in some real estate activities; the hospital is NABH accredited and emphasizes surgical excellence with a state‑of‑the‑art operation theatre and a history dating back to 1989. For the half year ended September 30, 2025 the company reported standalone revenue of Rs.1,894.82 lakhs and a net profit of Rs.63.58 lakhs, with quarter revenue around Rs.943.45 lakhs and profit before tax of Rs.88.59 lakhs, implying modest operating margins of roughly four to five percent and year‑on‑year revenue growth of about twenty percent. Financial and working capital metrics show rising stress: trade receivables increased to Rs.916.50 lakhs from Rs.694.35 lakhs year‑on‑year, inventories reached Rs.351.89 lakhs, short‑term borrowings surged to Rs.427.31 lakhs, and operating cash flow was negative Rs.250.65 lakhs in H1 despite a near stable cash balance of Rs.45.50 lakhs. Operational differentiation includes NABH accreditation, the company’s claim as the first centre in Rajasthan to perform replacement surgeries, launch of the S‑ROM Modular Hip System, and a specialized sterile OT, supporting institutional empanelments and reimbursement relationships that underpin referral volumes and revenue visibility for surgical services.
Over the past 52 weeks, Sharma East India Hosp and Medical Research Ltd has traded between a low of ₹74.00 and a high of ₹150.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sharma East India Hosp and Medical Research Ltd has a market capitalization of approximately 26.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sharma East India Hosp and Medical Research Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.28 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 26.31 Cr, Sharma East India Hosp and Medical Research Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sharma East India Hosp and Medical Research Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sharma East India Hosp and Medical Research Ltd is 23.28. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.